Close
  Indian J Med Microbiol
 

Figure 1: (a) Nonresponders to secukinumab. #There are 16 cases, but a patient (case 7) received adalimumab and ustekinumab separately, which makes n = 17. (b) Primary nonresponders to secukinumab. (c) Secondary nonresponders to secukinumab. *There are 9 cases, but a patient (case 7) received adalimumab and ustekinumab separately, which makes n = 10

Figure 1: (a) Nonresponders to secukinumab. <sup>#</sup>There are 16 cases, but a patient (case 7) received adalimumab and ustekinumab separately, which makes <i>n</i> = 17. (b) Primary nonresponders to secukinumab. (c) Secondary nonresponders to secukinumab. *There are 9 cases, but a patient (case 7) received adalimumab and ustekinumab separately, which makes <i>n</i> = 10